Home TMU Sitemap FAQ Links
正體中文
Home Ongoing Clinical Trials
Ongoing Clinical Trials

Institution
Principal Investigator
Protocol Title
Keyword
TMU-JIRB No. Protocol Title Institution / Principal Investigator Type of Study Phases of Clinical Trials for Drugs
N202606031 A Phase 3, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of rozanolixizumab in adult participants with ocular myasthenia gravis New Drug Phase Ⅲ
N202606032 A randomized, open-label (unblinding), three-period, reference-replicated, crossover bioequivalence study to compare two agomelatine F.C. tablets in healthy subjects under fasted state. Bioavailability / Bioequivalence (BA/BE) NA
N202606048 High-precision non-invasive continuous glucose monitoring wearable device technology development project: A study on the optimization of device algorithm based on physiological and metabolic indicators. New Medical Device NA
N202606086 An Open-Label, Randomized, and Crossover Bioequivalence Study of Cenobamate 12.5 mg Tablets in Healthy Subjects under Fasting Conditions New Drug Phase Ⅲ
N202606089 A Randomized, Double-blind, Parallel-group Phase III Study to Evaluate the Efficacy, Safety, and Tolerability of Elecoglipron Compared with Placebo in Adults with Type 2 Diabetes Mellitus and Impaired Renal Function on Background Dapagliflozin (Eluminate-4) New Drug Phase Ⅲ
N202606090 An Open-label, Multicenter Study of DPTX3186 to Evaluate Safety, Tolerability, and Pharmacokinetics in Subjects with Known Wnt-Pathway Activated Solid Tumors Where No Other Treatments Exist New Drug Phase Ⅰ
N202606091 A Phase 3, Open-Label, Extension Study to Evaluate the Long-Term Safety and Efficacy of Rozanolixizumab in Adult Participants With Ocular Myasthenia Gravis New Drug Phase Ⅲ
N202606093 A randomized, open-label (unblinding), crossover bioequivalence study to compare two dapagliflozin/metformin HCl ER tablets in healthy subjects under fed state. Bioavailability / Bioequivalence (BA/BE) NA
N202606094 A randomized, open-label (unblinding), crossover bioequivalence study to compare two dapagliflozin/metformin HCl ER tablets in healthy subjects under fasted state. Bioavailability / Bioequivalence (BA/BE) NA
N202606098 A Phase 1 First-in-human Study of BGM-2121 in Patients with Advanced Solid Tumors New Drug Phase Ⅰ
1 2 23 24 25 26 27 28 29 30 31 32 / 32

TOP